- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01841463
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
3 de septiembre de 2014 actualizado por: Piramal Enterprises Limited
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
- An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation
- The primary objective is to determine the safety, maximum tolerated dose (MTD), and dose limiting toxicity (DLT) of the co-administration of P1446A-05 with vemurafenib, in melanoma patients with BRAF mutation
Descripción general del estudio
Estado
Suspendido
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Anticipado)
100
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
California
-
South San Francisco, California, Estados Unidos, 94115
- UCSF Medical Center at Mount Zion
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Anschutz Medical Campus
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20057
- Georgetown-Lombardi Comprehensive Cancer Ctr
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas, MD Anderson Cancer Center
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Patients having histologically confirmed unresectable (Stage III) or metastatic (Stage IV) malignant melanoma with a positive BRAF mutation result determined by Roche CoDx or local CLIA-certified analysis
- Patients naïve to a selective BRAF inhibitor therapy or must have progressed after therapy on a selective BRAF inhibitor. For patients entering the protocol progressing on vemurafenib therapy, they must be tolerant of the 960 mg po bid dose.
- Tumor biopsies are optional in this study except for patients entering the mandatory biopsy cohorts. Nevertheless tumor biopsies are encouraged, especially in patients with accessible tumors for biopsy to include the collection of formalin-fixed, paraffin-embedded (FFPE) and fresh- frozen tissue (FF) as outlined in the biomarker sections of the protocol. Willingness of patient to give consent of biopsy, should be ascertained
- Patients of ≥ 18 years of age
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or1
- Patients with measurable disease per 'Response Evaluation Criteria In Solid Tumors' (RECIST version 1.1)
- Patients must have normal organ and adequate marrow function
- Patients with ability to swallow and retain oral medication
- Women of childbearing potential and men willing to agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the duration of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized.
- Negative serum pregnancy test within 10 days prior to commencement of therapy dosing in premenopausal women. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.
Ability to understand and the willingness to offer a written Informed Consent document prior to the screening procedures for participation into the study
- For Extension phase-
- For patients entering the protocol progressing on vemurafenib therapy, they must be tolerant of the vemurafenib dose selected for the extension phase
Exclusion Criteria:
- Prior malignancy (within the last 2 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the patient has been disease-free for at least 2 years
- Patients who have received any prior chemotherapy, radiotherapy, biologic/targeted anti-cancer therapy (one week for BRAF inhibitor for melanoma) or surgery within 4 weeks (6 weeks for monoclonal antibodies, radioactive monoclonal antibodies or any radio-or toxin-immunoconjugates) before Day 1 of Investigational product administration and have not recovered (to < Grade 1) from the toxic effects from any prior therapy
- Patients having received any other investigational agents within 4 weeks prior to Day 1 of Investigational product administration and have not recovered completely (to < Grade 1) from the side effects of the earlier investigational agent
- Anticipated administration of any anti-cancer therapies (chemotherapy, radiation therapy, immunotherapy, biological therapy, hormonal therapy, surgery, and/or tumor embolisation) other than those administered in this study such as BRAF inhibitor
- Patients with symptomatic or untreated leptomeningeal or brain metastases, or spinal cord compression [patients with previous brain metastases will be allowed to enter the trial if metastases have been surgically removed or all known sites of metastases have been treated with stereotactic high dose radiosurgery. Patients must be off corticosteroids for at least one month and have a stable lesion with verification by imaging (CT/MRI) within 28 days prior to Day 1 of Investigational product administration]
- Patients with clinically significant medical condition of malabsorption, inflammatory bowel disease, chronic diarrheal condition, refractory nausea, vomiting or any other condition that will interfere significantly with the absorption of study drugs
- Patients with mean QTc interval >480 msec at screening
- Treatment with drugs with potential to cause dysrhythmias including but not limited to terfenadine, quinidine, procainamide, diisopyramide, sotalol, probucol, bepridil, haloperidol, risperidone and/or indapamide
- Patients on warfarin treatment
- Any condition for which participation in this study as judged by the Investigator to be detrimental to the patient with (such as) inter-current illness including, but not limited to ongoing or active infection, New York Heart Association functional classification class III, or IV heart failure; unstable angina pectoris; cardiac arrhythmia; history of myocardial infarction; uncontrolled hypertension (blood pressure above 160/100 mm Hg despite antihypertensive treatment); coronary artery bypass graft; cerebrovascular accident; transient ischemic attack or pulmonary embolism during the previous 6 months or psychiatric illness/social situations that would jeopardize compliance with study requirements
- Patients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to any other medication chemically related to P1446A-05 or vemurafenib, or excipients considered to be clinically significant by the investigator
- Nursing woman
- Patients with known HIV positivity or AIDS- related illness, or active Hepatitis B virus, and active Hepatitis C virus
- Patients taking drugs known to prolong the QTc interval who cannot be switched to an alternative drug.
For Extension phase-
- Patients with active second malignancy will be eligible as long as they do not need systemic therapy for the second malignancy
- Patients with active brain metastases will be included in the study as long as the tumor size is less than 1 cm without the requirement of steroid use for neurological symptoms
- Patients with evaluable metastatic disease will be allowed even if there is no measurable disease per RECIST 1.1. In this case patients with many sub centimeter in-transit skin/SQ nodules will be eligible for the biopsy cohort.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: P1446A-05
|
- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) & vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group.
The max tolerated dose (MTD) of P1446A-05 & vemurafenib co-administered will be determined.
In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, & 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration.
Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples & undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Maximum Tolerated Dose and Dose Limiting Toxicity
Periodo de tiempo: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
The study will be conducted in two phases- Phase I (Dose escalation phase), and Extension phase.
In the Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group.
The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.
In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration.
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Tumor Response
Periodo de tiempo: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
- To determine best Overall Response Rate (ORR), Duration of response (DOR), Progression Free Survival (PFS), and Overall Survival (OS) of the co-administration of P1446A 05 and vemurafenib using RECIST version 1.1 in melanoma patients with BRAF mutation
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Pharmacokinetic (PK)
Periodo de tiempo: Cycle1 (Day 15 and 22) and Cycle 2 (Day1,15 and 28)
|
|
Cycle1 (Day 15 and 22) and Cycle 2 (Day1,15 and 28)
|
Biomarker Analysis
Periodo de tiempo: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Adil Daud, MD, UCSF Medical Center at Mount Zion
- Investigador principal: Kevin B Kim, MD, The University of Texas MD Anderson Cancer Center
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de agosto de 2013
Finalización primaria (Anticipado)
1 de marzo de 2015
Finalización del estudio (Anticipado)
1 de marzo de 2016
Fechas de registro del estudio
Enviado por primera vez
17 de abril de 2013
Primero enviado que cumplió con los criterios de control de calidad
23 de abril de 2013
Publicado por primera vez (Estimar)
26 de abril de 2013
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
4 de septiembre de 2014
Última actualización enviada que cumplió con los criterios de control de calidad
3 de septiembre de 2014
Última verificación
1 de septiembre de 2014
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Melanoma
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Vemurafenib
Otros números de identificación del estudio
- P1446A-05/72/12
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre P1446A-05
-
Tarsus Pharmaceuticals, Inc.Terminado
-
Tarsus Pharmaceuticals, Inc.Activo, no reclutandoVoluntario SaludableEstados Unidos
-
National Institute of Allergy and Infectious Diseases...Terminado
-
Cadila PharnmaceuticalsTerminadoMelanoma en estadio III o estadio IVEstados Unidos
-
CuraGen CorporationTerminado
-
Meridigen Biotech Co., Ltd.ReclutamientoSíndrome de FragilidadTaiwán
-
Centrexion TherapeuticsTerminado
-
Breath of Life International Pharma LtdRetirado
-
CuraGen CorporationTerminadoEstomatitis | Mucositis BucalEstados Unidos
-
Tarsus Pharmaceuticals, Inc.Terminado